• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Tilray Brands Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    11/6/24 5:02:18 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $TLRY alert in real time by email
    false000173134800017313482024-10-312024-10-31

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934

    Date of Report (Date of earliest event reported): November 6, 2024 (October 31, 2024)

    Tilray Brands, Inc.
    (Exact name of registrant as specified in its charter)

    Delaware
     
    001-38594
     
    82-4310622
    (State or other jurisdiction of incorporation)
     
    (Commission File Number)
     
    (IRS Employer Identification No.)

    265 Talbot Street West, Leamington, Ontario, Canada, N8H 4H3
    (Address of principal executive offices, including zip code)

    Registrant’s telephone number, including area code: (844) 845-7291

    Not Applicable
    (Former name or former address, if changed since last report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class
     
    Trading Symbol(s)
     
    Name of each exchange on which
    registered
    Common stock, par value $0.0001 per share
     
    TLRY
     
    The NASDAQ Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Sec. 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Sec. 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 8.01.
    Other Events

    On October 31, 2024, Nabil Salama, on behalf of a putative class of stockholders of Tilray Brands, Inc., a Delaware corporation (“Tilray”), as a nominal defendant, filed a Verified Stockholder Class Action Complaint in the Court of Chancery of the State of Delaware (the “Court”), naming Tilray and each member of the Board of Directors of Tilray, as defendants (the “Action”).

    The complaint alleges that (a) the definitive proxy statement filed by Tilray for its 2024 Annual Meeting of Stockholders (the “2024 Proxy Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) on September 27, 2024 specifies that a majority-of-votes-cast voting standard, rather than a majority-of-outstanding-shares voting standard, is required for approval of the proposal to increase the number of shares of common stock authorized for issuance (the “2024 Authorized Shares Proposal”), (b) the proposal increasing the number of shares of common stock authorized for issuance (the “2023 Authorized Shares Proposal” and together with the 2024 Authorized Shares Proposal, the “Authorized Shares Proposals”) was not validly approved by the stockholders under a majority-of-votes-cast voting standard, and any related issuances of Common Stock were and are not validly authorized, and (c) the named directors of Tilray have breached their fiduciary duties by failing to make accurate disclosures regarding the Authorized Shares Proposals in the 2024 Proxy Statement and 2023 Proxy Statement.  The Action  seeks to enjoin Tilray from holding a vote on the 2024 Authorized Shares Proposal at the 2024 Annual Meeting of Stockholders and requests the Plaintiff and putative class of stockholders be awarded all costs and expenses.

    Tilray firmly disagrees with the allegations made in the complaint and intends to defend against the Action vigorously. Specifically, Tilray believes that the Authorized Shares Proposals and the “votes cast” standard for approval are consistent with the 2023 amendments to Section 242 of the Delaware General Corporation Law.  These statutory amendments lowered the stockholder vote threshold for changes to a corporation’s authorized shares to a “majority of the votes cast” standard for companies with shares listed for trading on a national exchange, like Tilray. As previously reported, Tilray obtained the approval of a majority of stockholder “votes cast” on the 2023 Authorized Shares Proposal, with 208.6 million shares voted in favor of the proposal, compared to 85.2 million shares voting against (and 9 million shares abstaining). Given the overwhelming shareholder approval of the 2023 Authorized Shares Proposal, Tilray is seeking stockholder approval of the 2024 Authorized Shares Proposal.

    Management believes that the availability of additional authorized shares of Common Stock would enhance the Company’s business and financial flexibility and allow it to pursue strategic objectives, including potential acquisitions.  Notably, Institutional Shareholder Services Inc. (“ISS”) recommended that Tilray shareholders vote “FOR” the proposal to increase its authorized shares at the upcoming annual meeting of shareholders on November 21, 2024. Specifically, ISS stated that this proposal was warranted given that the proposed increase in the number of authorized shares of common stock is reasonable, and there are no substantial concerns about Tilray’s past use of shares.

    A copy of the Verified Stockholder Class Action Complaint in the form filed with the Court is attached as Exhibit 99.1 to this Current Report on Form 8-K.

    Supplemental Disclosures to Proxy Statement
    The disclosures contained in the Current Report on Form 8-K are also being filed as definitive additional materials on Schedule 14A, and should also be read as supplemental information as part of, the 2024 Proxy Statement, which should be read in its entirety and is on the SEC’s website at http://www.sec.gov, along with periodic reports and other information Tilray files with the SEC. To the extent that the information set forth herein differs from or updates information contained in the 2024 Proxy Statement, the information set forth herein shall supersede or supplement the information in the 2024 Proxy Statement. To the extent defined terms are used but not defined herein, they have the meanings set forth in the 2024 Proxy Statement.

    Participants in the Solicitation
    The directors and executive officers of Tilray and other persons may be considered participants in the solicitation of proxies from stockholders in connection with the proposed transaction. Information regarding Tilray’s directors and executive officers is available in the 2024 Proxy Statement for the 2024 Annual Meeting of Stockholders to be held on November 21, 2024 (and any adjournment or postponement thereof), which was filed with the Commission on September 27, 2024, and Tilray’s other filings with the SEC. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests is contained in the 2024 Proxy Statement.

    Cautionary Statement Concerning Forward-Looking Statements
    Certain statements in this Current Report on Form 8-K constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication.


    Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, Tilray’s intentions regarding the Action and its beliefs regarding the vote standard applicable to its Authorized Shares Proposals. Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of the Company and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of the Company made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

    Item 9.01.
    Financial Statements and Exhibits.

    (d)
    Exhibits.

    Exhibit
    Number
     
    Exhibit Description
    99.1
     
    Verified Stockholder Class Action Complaint in the Court of Chancery of the State of Delaware
         
    104
     
    Cover Page Interactive Data File (embedded within the Inline XBRL document).


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     
    TILRAY, INC.
         
    Dated: November 6, 2024
    By:
    /s/ Mitchell Gendel
       
    Mitchell Gendel
       
    Global General Counsel



    Get the next $TLRY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TLRY

    DatePrice TargetRatingAnalyst
    1/27/2026Hold
    Canaccord Genuity
    4/5/2024$2.25 → $2.75Neutral
    Alliance Global Partners
    11/2/2022$3.90Mkt Perform
    Bernstein
    7/29/2022$3.00Hold → Sell
    The Benchmark Company
    3/4/2022$9.00Hold → Buy
    Canaccord Genuity
    1/11/2022$7.40 → $6.90Neutral
    Cantor Fitzgerald
    1/7/2022$11.80 → $7.40Neutral
    Cantor Fitzgerald
    11/18/2021$10.00Underweight
    Barclays
    More analyst ratings

    $TLRY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tilray Brands Enters Agreement to Acquire BrewDog's Key U.S. Assets, Expanding Its U.S. Craft Beer Platform

    NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray", "our", "we" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a leading global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis, and wellness industries, today announced that the Company has entered into an asset purchase agreement to acquire certain strategic assets of BrewDog in the United States, including its brewery, pub, and hotel in Columbus, Ohio, as well as the pubs in New Albany, Ohio, Cleveland, Ohio, and Las Vegas, Nevada. As one of the largest craft beer brands in Ohio, this acquisition aligns with Tilray's regional jewel strategy. Irwin D. Simon, Chairman and Chief Ex

    3/16/26 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Medical, CC Pharma, and 14U Pharma Announce Strategic Alliance with "gesund leben" Cooperation and Alliance Healthcare Deutschland to Accelerate Market Expansion and Strengthen Pharmacy Access Across Germany

    DENSBORN, Germany, March 12, 2026 (GLOBE NEWSWIRE) -- Tilray Pharma, the pharmaceutical division of Tilray Brands, Inc. (NASDAQ:TLRY, TSX:TLRY), has announced a strategic partnership with Tilray Medical, CC Pharma, 14U Pharma, and "gesund leben" cooperation, which is operated by Alliance Healthcare Deutschland. As one of Germany's largest pharmacy networks, Alliance Healthcare Deutschland runs 27 logistics centers across the country and supplies more than 10,000 pharmacies daily. This comprehensive distribution network is recognized as a leading support system for independent pharmacies, providing essential services, marketing resources, and purchasing benefits. It plays a vital role in en

    3/12/26 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Lighter. Cheaper. Funner. Pub Light Is Here.

    BEND, Ore., March 11, 2026 (GLOBE NEWSWIRE) -- Pub Beer, the Cheap Fun beer brand by Tilray Brands, Inc. (NASDAQ:TLRY, TSX:TLRY), today announced the launch of Pub Light, a new American-style light lager built for easy drinking and long hangs. With 99 calories and 4% ABV, Pub Light delivers everything fans expect from Pub Beer — just lighter, cheaper, and funner. Pub Light skips additives, gimmicks, and over‑engineered tasting notes in favor of what actually matters. Brewed with 100% malt and made without sugar, corn, rice, or filler ingredients, Pub Light is clean, crisp, and dry — a no‑nonsense lager designed to keep the good times going. Born from Pub Beer's "Cheap Fun" mindset, Pub

    3/11/26 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Global General Counsel Gendel Mitchell exercised 93,928 shares at a strike of $0.58, covered exercise/tax liability with 49,782 shares and bought $3,496 worth of shares (6,000 units at $0.58), increasing direct ownership by 8% to 698,287 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    8/4/25 4:06:19 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    President and CEO Simon Irwin D bought $100,106 worth of shares (165,000 units at $0.61), increasing direct ownership by 4% to 3,941,633 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    7/30/25 6:52:32 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Financial Officer Merton Carl A bought $19,939 worth of shares (33,500 units at $0.60), increasing direct ownership by 4% to 798,069 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    7/30/25 3:12:46 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    SEC Filings

    View All

    Tilray Brands Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits

    8-K - Tilray Brands, Inc. (0001731348) (Filer)

    3/2/26 4:31:58 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Tilray Brands Inc.

    10-Q - Tilray Brands, Inc. (0001731348) (Filer)

    1/8/26 5:03:39 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Brands Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Tilray Brands, Inc. (0001731348) (Filer)

    1/8/26 4:20:29 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Tilray

    Canaccord Genuity initiated coverage of Tilray with a rating of Hold

    1/27/26 9:29:20 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Alliance Global Partners reiterated coverage on Tilray with a new price target

    Alliance Global Partners reiterated coverage of Tilray with a rating of Neutral and set a new price target of $2.75 from $2.25 previously

    4/5/24 7:39:50 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Bernstein initiated coverage on Tilray with a new price target

    Bernstein initiated coverage of Tilray with a rating of Mkt Perform and set a new price target of $3.90

    11/2/22 6:37:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cohen Steven Michael exercised 12,438 shares at a strike of $8.99 (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    1/8/26 4:24:12 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    President and CEO Simon Irwin D exercised 706,216 shares at a strike of $0.58 and covered exercise/tax liability with 374,295 shares, increasing direct ownership by 7% to 4,826,493 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    8/4/25 4:07:08 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Financial Officer Merton Carl A exercised 93,928 shares at a strike of $0.58 and covered exercise/tax liability with 49,782 shares, increasing direct ownership by 5% to 920,497 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    8/4/25 4:06:42 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    Financials

    Live finance-specific insights

    View All

    Tilray Brands Acquires BrewDog Australia, Establishing Strategic Base to Accelerate Global Beverage and Consumer Products Growth Across the Asia-Pacific Region

    Acquisition Includes BrewDog's Profitable Australian Operations Including Brisbane Brewery and Two Flagship Bars Transaction Positions Tilray to Scale BrewDog Across Australia's National Retail and Grocery Channels and Introduce Broader Beverage Portfolio Across Asia-Pacific NEW YORK and BRISBANE, Australia, March 09, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray", "our", "we" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a leading global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, today announced the completion of the acquisition of BrewDog Brewing Australia Pty Ltd., including BrewDog's Australian brewing and pr

    3/9/26 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Brands Acquires BrewDog, a Leading Global Craft Brand, Creating a ~$500 Million Global Craft Beer and Beverage Platform

    Accretive Acquisition of Select Assets Includes Global Brand, UK Brewing Operations and 11 Strategic Brewpubs  Expected to Generate ~$200 Million in Annual Net Revenue and ~$6 - $8 Million of Adjusted EBITDA in Fiscal 2027 Tilray's Global Consolidated Net Revenue Expected to Reach ~$1.2 Billion on an Annualized Basis1 Conference Call Scheduled for 12:30pm ET NEW YORK and LONDON, March 02, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray", "our", "we" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a leading global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, today completed the acquisition of certain highly strategic

    3/2/26 10:17:01 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Brands to Announce Second Quarter Fiscal Year 2026 Financial Results on January 8, 2026

    NEW YORK and LEAMINGTON, Ontario, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, beverage and wellness industries, today announced that the Company will release its financial results for the second fiscal quarter which ended November 30, 2025, after the financial markets close on Thursday, January 8, 2026. Live Conference Call and Audio Webcast Tilray will host a live conference call, which will be webcast, to discuss these results at 4:30 PM Eastern Time on the same day. The webcast can be accessed on the Events & Presentations section of T

    12/22/25 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Tilray Brands Inc. (Amendment)

    SC 13G/A - Tilray Brands, Inc. (0001731348) (Subject)

    2/13/23 1:34:44 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Tilray Brands Inc.

    SC 13G - Tilray Brands, Inc. (0001731348) (Subject)

    2/10/23 4:41:36 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D filed by Tilray Brands Inc.

    SC 13D - Tilray Brands, Inc. (0001731348) (Filed by)

    7/22/22 4:30:22 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    Leadership Updates

    Live Leadership Updates

    View All

    Breckenridge Distillery Appoints Romano Beverage for Distribution in Illinois

    BRECKENRIDGE, Colo., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Breckenridge Distillery, an award-winning craft distillery and spirits brand owned by Tilray Brands, Inc. (NASDAQ:TLRY, TSX:TLRY), has announced appointment of Romano Beverage, a respected partner, to manage distribution responsibilities within the state. Romano Beverage, a trusted leader in beverage distribution, is now overseeing Breckenridge Distillery's full spirits collection across Illinois—including its celebrated bourbon whiskey, whiskey, rum, vodka, gin, and newly launched Mountain Shot. Romano's strong presence in Illinois and dedication to exceptional service make them the perfect partner to help Breckenridge Distillery thr

    2/4/26 8:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Terrapin Beer Co. Celebrates 20 Years of Iconic Wake-n-Bake Beer with Exciting Wake-n-Bake Off Event in Athens, GA

    ATHENS, Ga., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Terrapin Beer Co., a Tilray Beverages craft beer brand under Tilray Brands, Inc. (NASDAQ:TLRY, TSX:TLRY), is excited to announce the 20th anniversary of its Wake-n-Bake Coffee Oatmeal Imperial Stout seasonal beer and the annual Wake-n-Bake Off event on Sunday, January 26th, 2025, at the Terrapin taproom in Athens, GA. In celebration of its 20th anniversary, guests will have the chance to observe local restaurants competing to craft the finest dish featuring Terrapin's renowned Wake-n-Bake Beer. This event highlights culinary innovation and fosters community engagement through an array of sweet and savory tastings that showcase the rich flavor

    1/23/25 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Blue Point Brewing Launches Big Mo Brew to Raise Funds and Awareness for Men's Health During Movember

    PATCHOGUE, N.Y., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Blue Point Brewing Company, Long Island's original craft brewery and subsidiary of Tilray Brands, (NASDAQ:TLRY, TSX:TLRY), is proud to announce the continuation of its men's health awareness campaign in support of Movember. The month shines a light on key men's health issues—mental health, prostate cancer, and testicular cancer—encouraging open conversations and proactive engagement. To honor the initiative, Blue Point Brewing announced the special release of its classic double IPA, Big Mo, available at our brewery and retailers in Long Island, New York. This hazy double IPA, featuring prominent mosaic hops and an ABV of 8.0%, proud

    10/22/24 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care